China Medical System Holdings Ltd. engages in the production, marketing, promotion, and sale of drugs. The company employs 6,095 full-time employees The company went IPO on 2010-09-28. The firm's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The firm distributes its products within domestic market and to overseas markets.
根據最新的財務報表(Form-10K),China Medical System Holdings Limited 的總資產為 $19,198,淨isProfitable}為 $1,488
CHSYF 的關鍵財務比率是什麼?
China Medical System Holdings Limited 的流動比率為 10.64,淨利潤率為 18.11,每股銷售為 $3.39。
China Medical System Holdings Limited 的收入按細分市場或地理位置如何劃分?
China Medical System Holdings Limited 最大收入來源為 Pharmaceutical Products,在最近的收益報告中收入為 8,854,663,686。就地區而言,China 是 China Medical System Holdings Limited 的主要市場,收入為 8,854,663,686。
China Medical System Holdings Limited 是否盈利?
是的,根據最新的財務報表,China Medical System Holdings Limited 的淨利潤為 $1,488
China Medical System Holdings Limited 有負債嗎?
是的,China Medical System Holdings Limited 的負債為 1,803
China Medical System Holdings Limited 的流通股有多少?
China Medical System Holdings Limited 的總流通股為 2,439.52